The impact of admission procalcitonin on prognosis in acute coronary syndromes: a pilot study.
Available evidence on the prognostic role of procalcitonin levels in acute coronary syndromes (ACS) is so far controversial. To evaluate the association between procalcitonin, major cardiovascular events (MACE) and total mortality in acute coronary syndromes. Procalcitonin levels were measured in 247 patients admitted to our Intensive Cardiac Care Unit (ICCU) with ACS. Three subgroups were considered according to procalcitonin levels. At Cox regression analysis, procalcitonin levels were both an unadjusted and an adjusted predictor (corrected for diagnosis and TnI) of intra-ICCU mortality and of 1-year follow-up MACE and total mortality. In ACS, admission procalcitonin values identify a "higher risk" group of patients for short and long-term mortality.